Very interesting statement by Ann Leen, Chief Science Officer of Marker, at 1:04 of Marker's ASGCT presentation, which is available on the front page of the Marker website>
Leen says that Marker's cell therapies have achieved "epitope spreading" where Yescarta and Kmyriah have not.
"Epitope spreading" is when the cell therapy causes inflamation at the tumor site, modifying the tumor microenvironment, lysing the cancer cells, and permitting the immune system to respond to the tumor.
Marker measures "epitope spreading" by gene sequencing the patient's T-cells and identifying the specific tumor protein epitopes which the T-cells are attacking. Marker finds that, 6 months after therapy cell infusion, the patients T-cells are targeting many TAAs which were not targeted by the Marker peptides.